Enter inventor name

John R McCullough

This inventor holds 32 USPTO granted patents, primarily in Pharmaceutical Compositions. Top assignees: Sepracor, Inc., University of Massachusetts. Active years: 1996-2007.

USPTO Granted Patents = 32

% Patents Active = 93.8

Average Co-Inventor Count = 2.3

ph-index = 14

Forward Citations = 720(Granted Patents)

Location History:

Hudson, MA (US) (2000 - 2003)
Worcester, MA (US) (1996 - 2007)

Company Filing History:

University of Massachusetts

patents

where one patent can have more than one assignee

Years Active: 1996-2007

Loading Chart...

Areas of Expertise:

Descarboethoxyloratadine

Norcisapride

Bupropion

Urinary Incontinence

Chronic Disorders

Allergic Rhinitis

Gastroesophageal Reflux

CNS Disorders

Smoking Cessation

Hydroxyitraconazole

32 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7214684 - Methods for the treatment of allergic rhinitis (2007-05-08),

2. 7214683 - Compositions of descarboethoxyloratadine (2007-05-08),

3. 7211582 - Methods for treating urticaria using descarboethoxyloratadine (2007-05-01),

4. 6632827 - Compositions of optically pure (+) norcisapride (2003-10-14),

5. 6495605 - Methods and compositions for aiding in smoking cessation and for treating pain and other disorders using optically pure (+)-bupropion (2002-12-17),

6. 6458374 - Methods and compositions for treating chronic disorders using optically pure (+)-bupropion (2002-10-01),

7. 6455530 - 2R,4S,S,S- and 2S,4R,S,S-hydroxyitraconazole (2002-09-24),

8. 6342496 - Bupropion metabolites and methods of use (2002-01-29),

9. 6313144 - Compositions of optically pure (−) norcisapride (2001-11-06),

10. 6242465 - Compositions of optically pure (+) norcisapride (2001-06-05),

11. 6207681 - Methods and compositions for treating urinary incontinence using enantiomerically enriched (R)-trihexyphenidyl (2001-03-27),

12. 6204285 - Methods and compositions for treating urinary incontinence using enantiomerically enriched (R,R)-glycopyrrolate (2001-03-20),

13. 6166018 - 2R, 4S, R, S- and 2S, 4R, R, S-hydroxyitraconazole (2000-12-26),

14. 6156770 - Compositions of optically pure (-) norcisapride and another therapeutic (2000-12-05),

15. 6147093 - Methods for treating gastroesophageal reflux disease (2000-11-14),

Title: John R. McCullough: Innovator in Allergy Treatments

Introduction

John R. McCullough, based in Worcester, MA, is a notable inventor with a remarkable portfolio of 32 patents. His innovative work primarily focuses on advancements in allergy treatments, particularly through the development of novel compositions and methods.

Latest Patents

Among McCullough's latest patents are significant contributions pertaining to compositions of descarboethoxyloratadine (DCL). He has disclosed methods utilizing DCL, a metabolic derivative of loratadine, for treating allergic rhinitis and other disorders. Importantly, his methodologies aim to minimize the adverse side effects commonly associated with other non-sedating antihistamines.

Career Highlights

Throughout his career, McCullough has made substantial impacts in the pharmaceutical industry. He has worked with Sepracor, Inc., where his expertise contributed to the development of various allergy medication innovations. Additionally, his tenure at the University of Massachusetts provided him the platform to advance research in allergy treatments.

Collaborations

In his professional journey, McCullough has collaborated with esteemed colleagues such as Thomas P. Jerussi and Vincent L. Fabiano. These partnerships have fostered a rich collaborative environment conducive to innovation and technological advancement in the field of allergy treatment.

Conclusion

John R. McCullough's contributions through his patents illustrate his commitment to enhancing patient care by improving allergy treatment methods. His work continues to impact the pharmaceutical landscape, showcasing the significance of innovation in addressing common health issues.

Profile summary based on public USPTO records.

Please report any incorrect information to [email protected]